Literature DB >> 17307535

Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.

Nandkishor S Kabra1, Barbara Schmidt, Robin S Roberts, Lex W Doyle, Luann Papile, Avroy Fanaroff.   

Abstract

OBJECTIVES: To determine whether surgical closure of a patent ductus arteriosus (PDA) is a risk factor for bronchopulmonary dysplasia (BPD), severe retinopathy of prematurity (ROP), and neurosensory impairment in extremely low birth weight (ELBW) infants. STUDY
DESIGN: We studied 426 infants with a symptomatic PDA, 110 of whom underwent PDA ligation and 316 of whom received medical therapy only. All infants participated in the multicenter Trial of Indomethacin Prophylaxis in Preterms (TIPP) and were observed to a corrected age of 18 months.
RESULTS: Of the 95 infants who survived after PDA ligation, 50 (53%) had neurosensory impairment, compared with 84 of the 245 infants (34%) who survived after receiving only medical therapy (adjusted odds ratio, 1.98; 95% CI, 1.18-3.30; P = .0093). BPD (adjusted odds ratio, 1.81; 95% CI, 1.09-3.03; P = .023) and severe ROP (adjusted odds ratio, 2.20; 95% CI, 1.19-4.07; P = .012) were also more common after surgical PDA closure.
CONCLUSIONS: PDA ligation may be associated with increased risks of BPD, severe ROP, and neurosensory impairment in ELBW infants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307535     DOI: 10.1016/j.jpeds.2006.11.039

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  83 in total

1.  The Patent Ductus Arteriosus Problem: Infants Who Still Need Treatment.

Authors:  Jeff Reese; Matthew M Laughon
Journal:  J Pediatr       Date:  2015-08-24       Impact factor: 4.406

Review 2.  Patent ductus arteriosus: evidence for and against treatment.

Authors:  Ronald I Clyman; Nancy Chorne
Journal:  J Pediatr       Date:  2007-03       Impact factor: 4.406

3.  Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants.

Authors:  Dany E Weisz; Lucia Mirea; Erin Rosenberg; Maximus Jang; Linh Ly; Paige T Church; Edmond Kelly; S Joseph Kim; Amish Jain; Patrick J McNamara; Prakesh S Shah
Journal:  JAMA Pediatr       Date:  2017-05-01       Impact factor: 16.193

4.  Towards rational management of the patent ductus arteriosus: the need for disease staging.

Authors:  Patrick J McNamara; Arvind Sehgal
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-11       Impact factor: 5.747

5.  Acetaminophen to avoid surgical ligation in extremely low gestational age neonates with persistent hemodynamically significant patent ductus arteriosus.

Authors:  D E Weisz; F F Martins; L E Nield; A El-Khuffash; A Jain; P J McNamara
Journal:  J Perinatol       Date:  2016-04-07       Impact factor: 2.521

6.  Patent ductus arteriosus in premature infants: A never-closing act.

Authors:  Bernard Thébaud; Thierry Lacaze-Mazmonteil
Journal:  Paediatr Child Health       Date:  2010-05       Impact factor: 2.253

7.  Treatment and Nontreatment of the Patent Ductus Arteriosus: Identifying Their Roles in Neonatal Morbidity.

Authors:  Ronald I Clyman; Melissa Liebowitz
Journal:  J Pediatr       Date:  2017-07-11       Impact factor: 4.406

8.  Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.

Authors:  Juliette C Madan; Douglas Kendrick; James I Hagadorn; Ivan D Frantz
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

Review 9.  Neonatal pain control and neurologic effects of anesthetics and sedatives in preterm infants.

Authors:  Christopher McPherson; Ruth E Grunau
Journal:  Clin Perinatol       Date:  2013-12-17       Impact factor: 3.430

10.  Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants.

Authors:  Samantha Ngo; Jochen Profit; Jeffrey B Gould; Henry C Lee
Journal:  Pediatrics       Date:  2017-04       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.